Regeneron Pharmaceuticals News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

26.07.17	Generali Global Assistance Publishes White Paper On The Benefits Of Adding Identity Protection Services To Customer Loyalty Programs (PR Newswire)
24.07.17	One Step Closer To EU Approval... (RTTNews)
21.07.17	Regeneron, Sanofi Get Positive CHMP Opinion For Dupixent - Quick Facts (RTTNews)
21.07.17	Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
13.07.17	Regeneron to Report Second Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2017 (PR Newswire)
13.07.17	Regeneron Announces the 2017 Winners of the Regeneron Prize for Creative Innovation (PR Newswire)
10.07.17	Daily Technical Summary Reports on Biotech Stocks -- PTC Therapeutics, Portola Pharma, Regeneron Pharma, and Seattle Genetics (PR Newswire)
27.06.17	Regeneron: EC Okays Kevzara To Treat Moderately To Severely Active RA (RTTNews)
27.06.17	Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union (PR Newswire)
21.06.17	Regeneron Recognized on "The Civic 50" List of the Most Community-Minded Companies in the United States (PR Newswire)
12.06.17	LXRX Brings Sweet Tidings, PFE's PROSPER Ahead Of Schedule, XBIT Fails To Excite (RTTNews)
12.06.17	Sanofi Announces Results From Two Phase 3b/4 ODYSSEY-DM Trials In Diabetes (RTTNews)
11.06.17	Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia (PR Newswire)
11.06.17	Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia (PR Newswire)
04.06.17	Regeneron, Sanofi Present Positive Study Results For PD-1 Antibody REGN2810 (RTTNews)
04.06.17	Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
24.05.17	Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFH (PR Newswire)
22.05.17	Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients (PR Newswire)
22.05.17	Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients (PR Newswire)
18.05.17	AWO Welcomes Inclusion of Vessel Discharge Reform, Waterway Tender Recapitalization in Coast Guard Authorization Bill (PR Newswire)
18.05.17	Regeneron Announces Upcoming Investor Conference Presentations (PR Newswire)
08.05.17	Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer (PR Newswire)
08.05.17	Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy (PR Newswire)
05.05.17	Regeneron Announces Upcoming Investor Conference Presentations (PR Newswire)
04.05.17	Regeneron Extending Recent Strong Move To The Upside (RTTNews)
04.05.17	Regeneron Pharmaceuticals Profit Rises 23% In Q1 (RTTNews)
04.05.17	Regeneron Reports First Quarter 2017 Financial and Operating Results (PR Newswire)
02.05.17	Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment (PR Newswire)
02.05.17	Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment (PR Newswire)
30.04.17	Monday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda (RTTNews)
28.04.17	Sanofi: FDA Sets New Action Date For Kevzara BLA As May 22, 2017 - Quick Facts (RTTNews)
28.04.17	Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA (PR Newswire)
26.04.17	AKBA Jumps On Otsuka Deal, MNOV Abuzz, CAPR Counting On HOPE... (RTTNews)
25.04.17	Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection (PR Newswire)
24.04.17	Sanofi, Regeneron Say Kevzara Gets CHMP Positive Opinion For RA In Adults (RTTNews)
14.04.17	Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017 (PR Newswire)
05.04.17	Biotech Stocks on Investors' Radar -- Puma Biotechnology, Regeneron Pharma, Calithera, and Lexicon Pharma (PR Newswire)
29.03.17	First Drug For 2 Forms Of MS Gets FDA Nod, RTTR Abuzz, VRTX Gains On Trial Data (RTTNews)
29.03.17	Regeneron Says FDA Okays New Eczema Drug Dupixent (RTTNews)
28.03.17	Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval (PR Newswire)
28.03.17	Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
28.03.17	Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
23.03.17	U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis (PR Newswire)
15.03.17	Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017 (PR Newswire)
15.03.17	Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017 (PR Newswire)
07.03.17	Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions (PR Newswire)
05.03.17	Regeneron, Sanofi: DUPIXENT Study In Atopic Dermatitis Shows Positive Data (RTTNews)
27.02.17	Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses (PR Newswire)
27.02.17	Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses (PR Newswire)
27.02.17	Biotech Stocks Facing FDA Decision In March (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen
31.10.24		NASDAQ-Handel NASDAQ 100 schlussendlich in Rot
31.10.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone
31.10.24		NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell
31.10.24		Zurückhaltung in New York: So performt der NASDAQ 100 aktuell
31.10.24		Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus
31.10.24		Zurückhaltung in New York: NASDAQ 100 zum Handelsstart im Minus
31.10.24		Donnerstagshandel in New York: NASDAQ Composite verliert zum Handelsstart